Retraction: Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy (Science Translational Medicine (2014) 6 (250ra112) DOI: 10.1126/scitranslmed.3009612);Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy

Science Translational Medicine

Volumn 6, Issue 250, 2014, Pages

  Azakir, Bilal A ^a   Erne, Beat ^a   Di Fulvio, Sabrina ^a   Stirnimann, Guido ^a   Sinnreich, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DYSFERLIN; BORONIC ACID DERIVATIVE; DYSF PROTEIN, HUMAN; MEMBRANE PROTEIN; MUSCLE PROTEIN; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSFERLIN GENE; GENE EXPRESSION; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MISSENSE MUTATION; MONOCYTE; MUSCLE BIOPSY; MUSCLE CELL; MUSCULAR DYSTROPHY; SARCOLEMMA; SINGLE DRUG DOSE; SKELETAL MUSCLE; ALLELE; CELL CULTURE; CELL MEMBRANE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUSCULAR DYSTROPHIES; MYOBLAST;

ADMINISTRATION, INTRAVENOUS; ADULT; ALLELES; BORONIC ACIDS; CELL MEMBRANE; CELLS, CULTURED; HUMANS; MALE; MEMBRANE PROTEINS; MONOCYTES; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES; MUTATION, MISSENSE; MYOBLASTS; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84907389831     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan8388     Document Type: Erratum

References (38)

1. J. Liu, M. Aoki, I. Illa, C. Wu, M. Fardeau, C. Angelini, C. Serrano, J. A. Urtizberea, F. Hentati, M. B. Hamida, S. Bohlega, E. J. Culper, A. A. Amato, K. Bossie, J. Oeltjen, K. Bejaoui, D. McKenna-Yasek, B. A. Hosler, E. Schurr, K. Arahata, P. J. de Jong, R. H. Brown Jr., Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20, 31-36 (1998).
2. R. Bashir, S. Britton, T. Strachan, S. Keers, E. Vafiadaki, M. Lako, I. Richard, S. Marchand, N. Bourg, Z. Argov, M. Sadeh, I. Mahjneh, G. Marconi, M. R. Passos-Bueno, S. Moreira Ede, M. Zatz, J. S. Beckmann, K. Bushby, A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 20, 37-42 (1998).
3. I. Illa, C. Serrano-Munuera, E. Gallardo, A. Lasa, R. Rojas-García, J. Palmer, P. Gallano, M. Baiget, C. Matsuda, R. H. Brown, Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 49, 130-134 (2001).
4. C. Therrien, D. Dodig, G. Karpati, M. Sinnreich, Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. J. Neurol. Sci. 250, 71-78 (2006).
5. N. De Luna, A. Freixas, P. Gallano, L. Caselles, R. Rojas-Garcia, C. Paradas, G. Nogales, R. Dominguez-Perles, L. Gonzalez-Quereda, J. J. Vilchez, C. Marquez, J. Bautista, A. Guerrero, J. A. Salazar, A. Pou, I. Illa, E. Gallardo, Dysferlin expression in monocytes: A source of mRNA for mutation analysis. Neuromuscul. Disord. 17, 69-76 (2007).
6. K. R. Doherty, E. M. McNally, Repairing the tears: Dysferlin in muscle membrane repair. Trends Mol. Med. 9, 327-330 (2003).
7. D. Bansal, K. Miyake, S. S. Vogel, S. Groh, C. C. Chen, R. Williamson, P. L. McNeil, K. P. Campbell, Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423, 168-172 (2003).
8. B. A. Azakir, S. Di Fulvio, J. Kinter, M. Sinnreich, Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J. Biol. Chem. 287, 10344-10354 (2012).
9. L. Klinge, J. Harris, C. Sewry, R. Charlton, L. Anderson, S. Laval, Y. H. Chiu, M. Hornsey, V. Straub, R. Barresi, H. Lochmüller, K. Bushby, Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 41, 166-173 (2010).
10. D. J. Kuhn, Q. Chen, P. M. Voorhees, J. S. Strader, K. D. Shenk, C. M. Sun, S. D. Demo, M. K. Bennett, F. W. van Leeuwen, A. A. Chanan-Khan, R. Z. Orlowski, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281-3290 (2007).
11. D. Chauhan, Z. Tian, B. Zhou, D. Kuhn, R. Orlowski, N. Raje, P. Richardson, K. C. Anderson, In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Cancer Res. 17, 5311-5321 (2011).
12. D. Siegel, T. Martin, A. Nooka, R. D. Harvey, R. Vij, R. Niesvizky, A. Z. Badros, S. Jagannath, L. McCulloch, K. Rajangam, S. Lonial, Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98, 1753-1761 (2013).
13. D. S. Siegel, T. Martin, M.Wang, R. Vij, A. J. Jakubowiak, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina, A. Chanan-Khan, F. Buadi, F. J. Reu, G. Somlo, J. Zonder, K. Song, A. K. Stewart, E. Stadtmauer, L. Kunkel, S. Wear, A. F. Wong, R. Z. Orlowski, S. Jagannath, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2817-2825 (2012).
14. P. G. Richardson, R. Baz, L. Wang, A. J. Jakubowiak, D. Berg, G. Liu, N. Gupta, A. Di Bacco, A. Hui, S. Lonial, Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): Results from the expansion cohorts of a phase 1 dose-escalation study. Blood (ASH Annual Meeting Abstracts) 118, Abstract 301 (2011).
15. S. K. Kumar, V. Roy, C. Reeder, B. R. LaPlant, M. Q. Lacy, M. A. Gertz, K. Laumann, M. A. Thompson, T.Witzig, F. K. Buadi, C. E. Rivera, J. R. Mikhael, P. L. Bergsagel, L. Hwa, S. V. Rajkumar, A. Dispenzieri, Phase 2 trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib. Blood (ASH Annual Meeting Abstracts) 122, Abstract 1994 (2013).
16. N. Wein, A. Avril, M. Bartoli, C. Beley, S. Chaouch, P. Laforêt, A. Behin, G. Butler-Browne, V. Mouly, M. Krahn, L. Garcia, N. Lévy, Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum. Mutat. 31, 136-142 (2010).
17. A. Aartsma-Rus, K. H. Singh, I. F. Fokkema, I. B. Ginjaar, G. J. van Ommen, J. T. den Dunnen, S. M. van der Maarel, Therapeutic exon skipping for dysferlinopathies? Eur. J. Hum. Genet. 18, 889-894 (2010).
18. M. Krahn, N. Wein, M. Bartoli, W. Lostal, S. Courrier, N. Bourg-Alibert, K. Nguyen, C. Vial, N. Streichenberger, V. Labelle, D. DePetris, C. Pécheux, F. Leturcq, P. Cau, I. Richard, N. Lévy, A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci. Transl. Med. 2, 50ra69 (2010).
19. B. A. Azakir, S. Di Fulvio, S. Salomon, M. Brockhoff, C. Therrien, M. Sinnreich, Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J. Biol. Chem. 287, 27629-27636 (2012).
20. W. Lostal, M. Bartoli, N. Bourg, C. Roudaut, A. Bentaïb, K. Miyake, N. Guerchet, F. Fougerousse, P. McNeil, I. Richard, Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet. 19, 1897-1907 (2010).
21. W. E. Grose, K. R. Clark, D. Griffin, V. Malik, K. M. Shontz, C. L. Montgomery, S. Lewis, R. H. Brown Jr., P. M. Janssen, J. R. Mendell, L. R. Rodino-Klapac, Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLOS One 7, e39233 (2012).
22. B. Wang, Z. Yang, B. K. Brisson, H. Feng, Z. Zhang, E. M. Welch, S. W. Peltz, E. R. Barton, R. H. Brown Jr., H. L. Sweeney, Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J. Appl. Physiol. 109, 901-905 (2010).
23. V. Schoewel, A. Marg, S. Kunz, T. Overkamp, R. S. Carrazedo, U. Zacharias, P. T. Daniel, S. Spuler, Dysferlin-peptides reallocate mutated dysferlin thereby restoring function. PLOS One 7, e49603 (2012).
24. J. Díaz-Manera, T. Touvier, A. Dellavalle, R. Tonlorenzi, F. S. Tedesco, G. Messina, M. Meregalli, C. Navarro, L. Perani, C. Bonfanti, I. Illa, Y. Torrente, G. Cossu, Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis. 1, e61 (2010).
25. M. Sinnreich, C. Therrien, G. Karpati, Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66, 1114-1116 (2006).
26. S. Bringhen, A. Larocca, D. Rossi, M. Cavalli, M. Genuardi, R. Ria, S. Gentili, F. Patriarca, C. Nozzoli, A. Levi, T. Guglielmelli, G. Benevolo, V. Callea, V. Rizzo, C. Cangialosi, P. Musto, L. De Rosa, A. M. Liberati, M. Grasso, A. P. Falcone, A. Evangelista, M. Cavo, G. Gaidano, M. Boccadoro, A. Palumbo, Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116, 4745-4753 (2010).
27. P. G. Richardson, W. Xie, C. Mitsiades, A. A. Chanan-Khan, S. Lonial, H. Hassoun, D. E. Avigan, A. L. Oaklander, D. J. Kuter, P. Y. Wen, S. Kesari, H. R. Briemberg, R. L. Schlossman, N. C. Munshi, L. T. Heffner, D. Doss, D. L. Esseltine, E. Weller, K. C. Anderson, A. A. Amato, Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27, 3518-3525 (2009).
28. D. E. Reece, D. Sullivan, S. Lonial, A. F. Mohrbacher, G. Chatta, C. Shustik, H. Burris 3rd, K. Venkatakrishnan, R. Neuwirth, W. J. Riordan, M. Karol, L. L. von Moltke, M. Acharya, P. Zannikos, A. Keith Stewart, Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother. Pharmacol. 67, 57-67 (2011).
29. G. Benevolo, A. Larocca, M. Gentile, P. Pregno, F. Gay, B. Botto, C. Frairia, A. Evangelista, F. Morabito, M. Boccadoro, U. Vitolo, A. Palumbo, The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer 117, 1884-1890 (2011).
30. P. Moreau, H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, M. Grishunina, G. Rekhtman, Z. Masliak, T. Robak, A. Shubina, B. Arnulf, M. Kropff, J. Cavet, D. L. Esseltine, H. Feng, S. Girgis, H. van de Velde, W. Deraedt, J. L. Harousseau, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431-440 (2011).
31. A. Broyl, S. L. Corthals, J. L. Jongen, B. van der Holt, R. Kuiper, Y. de Knegt, M. van Duin, L. el Jarari, U. Bertsch, H. M. Lokhorst, B. G. Durie, H. Goldschmidt, P. Sonneveld, Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 11, 1057-1065 (2010).
32. A. Badros, O. Goloubeva, J. S. Dalal, I. Can, J. Thompson, A. P. Rapoport, M. Heyman, G. Akpek, R. G. Fenton, Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer 110, 1042-1049 (2007).
33. C. S. Denlinger, N. J. Meropol, T. Li, N. L. Lewis, P. F. Engstrom, L. M. Weiner, J. D. Cheng, R. K. Alpaugh, H. Cooper, J. J. Wright, S. J. Cohen, A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin. Colorectal Cancer 13, 81-86 (2014).
34. M. Ho, C. M. Post, L. R. Donahue, H. G. Lidov, R. T. Bronson, H. Goolsby, S. C. Watkins, G. A. Cox, R. H. Brown Jr., Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum. Mol. Genet. 13, 1999-2010 (2004).
35. E. Vafiadaki, A. Reis, S. Keers, R. Harrison, L. V. Anderson, T. Raffelsberger, S. Ivanova, H. Hoger, R. E. Bittner, K. Bushby, R. Bashir, Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuroreport 12, 625-629 (2001).
36. K. Censier, A. Urwyler, F. Zorzato, S. Treves, Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J. Clin. Invest. 101, 1233-1242 (1998).
37. K. Wenzel, M. Carl, A. Perrot, J. Zabojszcza, M. Assadi, M. Ebeling, C. Geier, P. N. Robinson, W. Kress, K. J. Osterziel, S. Spuler, Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum. Mutat. 27, 599-600 (2006).
38. K. H. Strucksberg, K. Tangavelou, R. Schröder, C. S. Clemen, Proteasomal activity in skeletal muscle: A matter of assay design, muscle type, and age. Anal. Biochem. 399, 225-229 (2010).